Osborne Clarke has advised iOnctura B.V. on the deal,iOnctura B.V., a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, has completed a €80 million Series B…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Marco Zingaro
…
This content is for Standard 1 Year members only. LoginJoin Now